The US Oncology Network | Strategic Alliance Partners

Latest from The US Oncology Network


Zanubrutinib Triplet Shows Early Promise in Treatment-Naive TP53-Mutant MCL

December 11, 2023

The combination comprised of zanubrutinib, obinutuzumab, and venetoclax elicited high response rates and 2-year progression-free survival rates that compared favorably with historical outcomes achieved with chemoimmunotherapy in high-risk patients with previously untreated mantle cell lymphoma harboring TP53 mutations.

Acalabrutinib With or Without Obinutuzumab Provides Sustained PFS Benefit in Previously Untreated CLL

December 11, 2023

Acalabrutinib, as monotherapy or in combination with obinutuzumab, continued to improve progression-free survival vs obinutuzumab and chemotherapy in patients with treatment-naive chronic lymphocytic leukemia, regardless of genomic marker status.

FDA Selects Ontada to Investigate the Natural History of Rare Cancers Treated in the U.S. Community Oncology Setting

October 26, 2023

Ontada®, a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, was awarded a competitive contract with the U.S. Food and Drug Administration to advance the use of real-world data in the U.S. community oncology setting.

Ontada Names Christine Davis Its New President

October 02, 2023

Ontada, a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, announced the appointment of Christine Davis as its new president.

Physicians Must Become Advocates to Play a Role in Community Oncology’s Future

September 25, 2023

Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.

Dr Monk on Avutometinib Plus Defactinib in Low-Grade Serous Ovarian Cancer

June 29, 2023

Bradley Monk, MD, FACS, FACOG, discusses findings from the phase 2 RAMP 201 trial in patients with low-grade serous ovarian cancer and the importance of these results within the context of the larger ovarian cancer treatment paradigm.